Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis

Autor:	K. Prajapati, Laura Airas, L. Mehta, K. Coutant, Marianna Manfrini, H. Koendgen, H.-P. Hartung, Bruno Brochet, Jerry S. Wolinsky, Ludwig Kappos, Robert T. Naismith
Rok vydání:	2019
Předmět:	medicine.medical_specialty business.industry medicine.medical_treatment Primary Progressive Multiple Sclerosis Neurology Internal medicine medicine In patient Disability progression Ocrelizumab Neurology (clinical) business Reduction (orthopedic surgery) medicine.drug
Zdroj:	Journal of the Neurological Sciences. 405:31
ISSN:	0022-510X
DOI:	10.1016/j.jns.2019.10.269
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b9082ce4e91d01f29d097d04fe17bc94 https://doi.org/10.1016/j.jns.2019.10.269 Zobrazit plný text záznamu Full Text from ScienceDirect